0001567619-21-011488.txt : 20210602 0001567619-21-011488.hdr.sgml : 20210602 20210602123450 ACCESSION NUMBER: 0001567619-21-011488 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210602 DATE AS OF CHANGE: 20210602 EFFECTIVENESS DATE: 20210602 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NERVGEN PHARMA CORP. CENTRAL INDEX KEY: 0001751912 IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-368217 FILM NUMBER: 21988395 BUSINESS ADDRESS: STREET 1: SUITE 1703 - 595 BURRARD STREET CITY: VANCOUVER STATE: A1 ZIP: V7X 1J1 BUSINESS PHONE: 6047225361 MAIL ADDRESS: STREET 1: SUITE 1703 - 595 BURRARD STREET CITY: VANCOUVER STATE: A1 ZIP: V7X 1J1 D/A 1 primary_doc.xml X0708 D/A LIVE 0001751912 NERVGEN PHARMA CORP. SUITE 1703 - 595 BURRARD STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA V7X 1J1 6047225361 BRITISH COLUMBIA, CANADA None None Corporation true 2017 Bill Radvak Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director Brian Bayley Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director Michael Abrams Suite 1703 - 595 Burrard Street Vanouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director Harold Punnett Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director Paul Brennan Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director Executive Officer Randall Kaye Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director William Adams Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Executive Officer Daniel Mikol Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Executive Officer Other Decline to Disclose 06b true 0001567619-20-011570 2020-05-20 true true true true Units consist of one common share and one common share purchase warrant, exercisable at CAD$1.60 per share for a period of 24 months, subject to acceleration. false 0 650123 285141 364982 (c) represents the maximum potential exercise price of warrants. Subscriptions paid in Canadian currency converted to US dollars at CAD$1.3892 = USD$1.00. false 13 0 0 0 false NERVGEN PHARMA CORP. /s/ William Adams William Adams CFO 2021-06-01